---
title: "CapForce Inc. (CFOR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CFOR.US.md"
symbol: "CFOR.US"
name: "CapForce Inc."
industry: "Biotechnology"
datetime: "2026-03-10T05:01:54.509Z"
locales:
  - [en](https://longbridge.com/en/quote/CFOR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CFOR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CFOR.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/CFOR.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/CFOR.US.md)


# CapForce Inc. (CFOR.US)

## Company Overview

CapForce Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company’s products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. In addition, the company offers listing sponsorship and consultancy services.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.opgen.com](https://www.opgen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: A
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-09T04:30:14.000Z

**Overall: A (0.18)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 5 / 407 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: A

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 610.97% |  |
| Net Profit YoY | 167.66% |  |
| P/B Ratio | 29.37 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 298367811.00 |  |
| Revenue | 9000000.00 |  |

#### Multi Score Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 102.11% | A |
| Profit Margin | 76.04% | A |
| Gross Margin | 0.00% | E |
| Revenue YoY | 610.97% | A |
| Net Profit YoY | 167.66% | A |
| Total Assets YoY | 131.07% | A |
| Net Assets YoY | 240.16% | A |
| Cash Flow Margin | 134.12% | C |
| OCF YoY | 610.97% | A |
| Turnover | 0.99 | A |
| Gearing Ratio | 19.63% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CapForce Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "610.97%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "167.66%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "29.37",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "298367811.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "9000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "102.11%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "76.04%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "610.97%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "167.66%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "131.07%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "240.16%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "134.12%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "610.97%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.99",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "19.63%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 45.37 | 53/407 | - | - | - |
| PB | 29.97 | 426/407 | - | - | - |
| PS (TTM) | 33.83 | 221/407 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CFOR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CFOR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CFOR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CFOR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**